Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women's healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. It is an integrated company with internal resources focused on the development, manufacture and promotion of its products. Its women's healthcare franchise is anchored by its presence in the hormonal contraceptive, osteoporosis and hormone therapy (HT) markets. The Company's hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product that offers women the lowest dosage of estrogen of any oral contraceptive.
|Headquarters||1 Grand Canal Square|
Docklands, Dublin 2
|President, Chief Executive Officer, Director||Roger Boissonneault|
|Chief Financial Officer, Executive Vice President, Director||Paul Herendeen|
|Senior Vice President - Finance||Rochelle Fuhrmann|
|Senior Vice President, Chief Information Officer||Andrew Fenton|
|Senior Vice President - Technical Operations||Leland Cross|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||250.8M||Book Value||$-2.40|
|Annual Dividend Rate||$0.50||Price/Sales (TTM)||2.0|
|Ex-Div Date||5/29/13||P/Cash Flow (TTM)||5.2x|
|Pay Date||5/29/13||Operating Margin||20.09%|
*GAAP = prior to non-GAAP analyst adjusted earnings.